Keryx Biopharmaceuticals Email Format

Biotechnology ResearchMassachusetts, United States51-200 Employees

As of December 13, 2018, Keryx Biopharmaceuticals merged with Akebia Therapeutics and now operates as Akebia, a single company focused on developing and delivering therapies for chronic kidney disease. The organization was part of the biotechnology research industry, headquartered in Boston, Massachusetts, United States, and employed between 51 and 200 people. Prior to the merger, Keryx developed Auryxia, an iron-based treatment used to manage iron deficiency anemia in adults with chronic kidney disease not on dialysis; Auryxia launched in the United States in December 2014 and received U.S. FDA approval in November 2017. Keryx also worked on Zerenex, an iron-based phosphate binder intended to treat elevated phosphate levels in ESRD. Current news and updates are now issued under Akebia, with information available via Akebia's LinkedIn page.

Sign up for free to view info

Company overview Employee directory